| Literature DB >> 20428045 |
Gabbriella Innocenti1, Stefano Dall'Acqua, Giuditta Scialino, Elena Banfi, Silvio Sosa, Khilendra Gurung, Mariagnese Barbera, Maria Carrara.
Abstract
The essential oil of Rhododendron anthopogon was investigated by GC-MS, and seventeen compounds (representing approximately 98% of the oil) were identified. The major components of the aerial parts of the oil were the monoterpenes alpha-pinene, beta-pinene, limonene and the sesquiterpene delta-cadinene. Biological studies revealed a weak topical anti-inflammatory activity; a significant killing effect against some Gram-positive reference strains: Staphylococcus aureus, Enterococcusfecalis, Bacillus subtilis was measured; Mycobacterium tuberculosis reference strain and a clinical isolate of Candida, C. pseudotropicalis were killed by as low as 0.04% (v/v) essential oil. Moreover, the oil was able to reduce cancer cell growth independently of the cell line and the treatment protocols used.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20428045 PMCID: PMC6257328 DOI: 10.3390/molecules15042326
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Chemical composition of R. anthopogon essential oil.
| Compound | RI a | RI b | Identification method | % |
|---|---|---|---|---|
| α -Thujene | 929 | 1018 | 1, 2 | 0.21 ± 0.01 |
| α -Pinene | 937 | 1032 | 1, 2, 3 | 37.40 ± 0.16 |
| Camphene | 954 | 1076 | 1, 2, 3 | 0.23 ± 0.02 |
| β-Pinene | 979 | 1118 | 1, 2, 3 | 15.98 ± 0.11 |
| β-Myrcene | 984 | 1174 | 1, 2, 3 | 1.10 ± 0.04 |
| 1023 | 1280 | 1, 2, 3 | 2.60 ± 0.06 | |
| Limonene | 1030 | 1203 | 1, 2, 3 | 13.3 ± 0.2 |
| 1050 | 1262 | 1, 2 | 5.32 ± 0.24 | |
| γ-Terpinene | 1062 | 1255 | 1, 2, 3 | 1.47 ± 0.07 |
| α-Copaene | 1364 | 1495 | 1, 2 | 0.74 ± 0.02 |
| 1420 | 1612 | 1, 2, 3 | 2.26 ± 0.06 | |
| α-Humulene | 1449 | 1687 | 1, 2, 3 | 0.20 ± 0.01 |
| 1461 | 1661 | 1, 2 | 0.23 ± 0.01 | |
| Germacrene D | 1480 | 1726 | 1, 2 | 1.77 ± 0.07 |
| α-Amorphene | 1485 | 1675 | 1, 2 | 3.15 ± 0.11 |
| α-Muurolene | 1499 | 1740 | 1, 2 | 2.74 ± 0.12 |
| δ-Cadinene | 1524 | 1773 | 1, 2 | 9.10 ± 0.15 |
a Kovats retention index calculated on DB-5 column; b Kovats retention indices calculated on HP INNOwax column; 1: Kovats retention index, 2: mass spectrum, 3: co-injection with authentic compounds.
The topical anti-inflammatory activity of R. anthopogon essential oil and indomethacin on croton oil induced ear oedema in mice.
| Group | Dose (µg/cm2) | Animal number | Weight mg ± E.S. | Oedema inhibition % |
|---|---|---|---|---|
| Controls | -- | 10 | 7.0 ± 0.3 | -- |
| 1,000 | 10 | 6.0 ± 0.6 | 14 | |
| 4,000 | 10 | 4.2 ± 0.2* | 40 | |
| Indomethacin | 100 | 10 | 3.0 ± 0.3* | 57 |
* Significantly different from control (p < 0.05).
Antibacterial activity of R. anthopogon essential oil, evaluated by microdilution assay.
| Strains | MIC (% v/v) |
|---|---|
| 2.5 | |
| 1.25 | |
| 0.04 | |
| >5 | |
| >5 | |
| 0.04 |
Ampicillin, ciprofloxacin, isoniazide, rifampicin MIC ranges: 0.05–0.1 g/mL
Antifungal activity of R. anthopogon essential oil, evaluated by microdilution assay.
| Clinical Strains | 24 h MIC (% v/v) | 48 h MIC (% v/v) |
|---|---|---|
| 0.08-0.04 | 0.3-0.15 | |
| 0.15 | 0.3 | |
| 0.15 | 0.6 | |
| 0.6-0.3 | 0.6 | |
| 0.3 | 2.5 | |
| 0.3 | 1.25 | |
| 0.04 | 0.15 | |
| 0.15 | 0.6 | |
| 1.25 | 5 | |
| 2.5 | >5 | |
| 1.25-0.6 | 1.25 | |
| 0.3 | 1.25 | |
| 0.3 | 1.25 | |
| 0.3 | 0.6 | |
| 0.04 | 0.04 |
Miconazole MIC range: 0.125–64 g/mL; Amphotericin B MIC range: 0.25–4 g/mL.
Figure 1% cell viability versus control of 2008, LoVo and A-31 cells treated with R. anthopogon essential oil (EO) for 3h + 21h incubation in culture medium (a) or 24h (b).
IC50 values and L.C. calculated by exposing 2008, LoVo and A-431cells to R. anthopogon essential oil with different treatment protocols.
| Time Treatment | |||||
|---|---|---|---|---|---|
| 3 h + 21 h | 24 h | 48 h | 72 h | ||
| Concentrations μg/mL | |||||
| 200, 400, 600 | 100, 200, 400 | 25, 50, 100, 200 | |||
| 246.1 | 224.0 | 186.4 | 154.2 | 159.7 | |
| (223.4-271.2) | (196.9-254.9) | (158.4-219.5) | (131.8-180.3) | (139.8-182.5) | |
| 213.5 | 218.6 | 146.2 | 108.5 | 118.1 | |
| (184.6-247.0) | (186.9-255.6) | (128.3-166.6) | (64.6-182.3) | (60.6-230.1) | |
| 236.6 | 217.6 | 75.3 | 41.5 | 41.3 | |
| (202.2-276.8) | (187.9-252.0) | (37.9-149.3) | (21.0-81.9) | (25.6-66.5) | |
Figure 2% cell viability versus control of 2008 (a), LoVo (b) and A-431(c) cells treated with R. anthopogon essential oil (EO) for 24, 48 or 72h.